Kolon Life Science

At a glance

Kolon Life Science filed 48 disclosures in the last 12 months, including 1 5% holder and 1 issuance. The most recent key filing was on Dec 2.

Revenue for 2025 was ₩209B, up 29.5% on 2024. Operating margin was 8.4% against -13.7% a year earlier. Debt was 57% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩100B and operating profit of ₩2.1B.

The 2025 annual report lists 454 employees with an average tenure of 7.7 years and average pay of ₩60.9M, #928 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩396M each on average. It paid no cash dividend for 2025. ㈜코오롱 and related parties held 42.46% at year end.

From the 2025 annual report

Staff: 454 (330 men, 124 women), of whom 20 on fixed-term contracts. Total pay for the year: ₩27.7B. Directors and auditors: 5, paid ₩2B in total.

No cash dividend was paid for 2025.

Largest shareholder

㈜코오롱 holds 25.11%; with 9 related parties the group holds 42.46% of common shares at year end (from 44.10% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary